EMEA-002141-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 March 2025 - 10:54
EMEA-002141-PIP01-17-M04
EMEA-002141-PIP01-17-M04
EMEA-001949-PIP02-18-M04
EMEA-001949-PIP01-16-M06
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0012/2024
Product Management Service (PMS) roadmap
Human medicines European public assessment report (EPAR): Silodyx, silodosin, Date of authorisation: 29/01/2010, Revision: 17, Status: Authorised
PSUSA/00010390/202407
PSUSA/00010598/202407
PSUSA/00002256/202407
Herbal medicinal product: Oleae folium, Olea europaea L., C: ongoing call for scientific data